Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 333 Cr.
- Current Price ₹ 333
- High / Low ₹ 448 / 198
- Stock P/E 135
- Book Value ₹ 196
- Dividend Yield 0.00 %
- ROCE 0.33 %
- ROE -0.36 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 2.89% over past five years.
- Company has a low return on equity of -1.93% over last 3 years.
- Earnings include an other income of Rs.8.49 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -5.67%
- Working capital days have increased from 237 days to 403 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 131 | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | 134 | |
| Operating Profit | -0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | -3 |
| OPM % | -0% | 3% | 4% | 10% | 29% | 22% | -14% | -12% | -8% | -2% |
| -0 | -0 | -0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | |
| Interest | -0 | -0 | -0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | -0 | -0 | -0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | -0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 3 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | ||
| -0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 2 | |
| EPS in Rs | -0.00 | 20.00 | 20.00 | 6,410.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 | 2.47 |
| Dividend Payout % | -0% | -0% | -0% | 4% | 7% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -23% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 165% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -23% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | -0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 | 186 |
| -0 | -0 | -0 | 10 | 4 | 4 | 3 | 2 | 4 | 3 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | 14 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
| -0 | -0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | 13 | |
| CWIP | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | 0 | 1 | 34 | 62 | 97 | 4 | 11 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | 189 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | |||
| -0 | -0 | -110 | -3 | -18 | 18 | 9 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | |||
| Net Cash Flow | -0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 |
| Inventory Days | -0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 |
| Working Capital Days | 182 | -12 | -45 | 85 | 61 | 109 | 148 | 160 | 403 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Oct - Nureca Limited has informed regarding Newspaper Publication.
-
Intimation Of SEBI ('SEBI') Order Under Section 11(1) Of SEBI Act, 1992 Read With Regulation 28 Of SEBI (Buy-Back Of Securities) Regulations, 2018 ('Buy-Back Regulations')
17 Oct - SEBI order (16 Oct 2025) permits buyback despite pending merger with wholly-owned subsidiary.
-
Nureca Limted Has informed Regarding Financial Results For The Quarter And Half Year Ended 30Th September,2025.
16 Oct - Board approved unaudited standalone and consolidated Q2/H1 results for period ended 30 Sep 2025; limited review attached.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Oct - Q2 FY26 revenue ₹37.7Cr (+21% YoY); H1 ₹71.9Cr (+40%); Q2 PAT ₹3.6Cr.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
16 Oct - Nureca Limited has informed regardig Investor Presentation.
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26